Clinical trials: Cellular Senescence
- Condition Cellular Senescence
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
COVID-19
Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above
This is a randomized, blinded, positive-controlled study to evaluate the immunogenicity and safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, in population aged 18 years old and above（negative antibody against…
- Trial name
- NCT05663086
- Testing
- One dose group, Two doses group, Aged 18-59 years
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Hand, Foot and Mouth Disease
An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell)
This is an open，observational and follow-up clinical trial based on the clinical trial of EV71 vaccine extended age group.The purpose of this study is to evaluate the immunity persistence of EV71 vaccine developed by Sinovac…
- Trial name
- NCT05397587
- Testing
- Experimental Vaccine, Control Vaccine
- Where
- China
- Volunteers
- 474 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
COVID-19
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
An open experimental design was used in this study, and 240 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) after sequential intensification in…
- Trial name
- NCT05895110
- Testing
- Recombinant Novel Coronavirus vaccine (CHO Cells)
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Herpes Zoster
Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
The purposes of the study are to evaluate the safety and tolerability of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 18 years and older, and to…
- Trial name
- NCT05636436
- Testing
- Low Dose Recombinant Herpes Zoster Vaccine (CHO cells), High Dose Recombinant Herpes Zoster Vaccine (CHO cells), Low dose adjuvant
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents
This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety…
- Trial name
- NCT04992208
- Testing
- Experimental Group
- Where
- China
- Volunteers
- 31,041 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Coronavirus
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)
Popular topic: Phase I clinical trial of recombinant new coronavirus vaccine (CHO cell) (3~17 years old) Research purpose:Main purpose:To evaluate the safety and tolerability of recombinant New Coronavirus vaccine (CHO cells) in…
- Trial name
- NCT04961359
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Poliomyelitis
Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)
The study aimed to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine in infants aged two months (60~89 days).
- Trial name
- NCT07297186
- Testing
- sIPV, wIPV
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Herpes Zoster
Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07892989
- Testing
- Recombinant Zoster Vaccine (CHO cell) SYS6052, Active Comparator Vaccine
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Herpes Zoster
Month 30 & 42 Extension Studies of CRD-004 Primary Study
The safety and immunogenicity of the GSK324332A vaccine has been evaluated up to Month 12 post-vaccination in the primary study.
- Trial name
- NCT00492648
- Testing
- Blood sampling for assay of persistence of immunogenicity
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup
The study primarily aims to evaluate immunogenicity and safety of influenza vaccines (cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free…
- Trial name
- NCT00579345
- Testing
- Cell culture derived seasonal trivalent influenza vaccine (cTIV), Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)., cTIV or eTIV_a
- Where
- 5 sites in Poland
- Volunteers
- 1,522 people, healthy volunteers welcome
- Sponsor
- Novartis
COVID-19
Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)
This is a multicenter designed Phase III clinical trial. About 10000 participants plan to be enrolled.The objectives of this study are to evaluate the efficacy, safety and immunogenicity of the recombinant two-component COVID-19…
- Trial name
- NCT05398848
- Testing
- Recombinant two-component COVID-19 vaccine (CHO cell)
- Where
- 11 sites in Nepal, Russia
- Volunteers
- 7,623 people, healthy volunteers welcome
- Sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.
Poliomyelitis
Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations
The goal of this clinical study is to compare the immunogenicity and safety of one dose of sIPV in adolescents or adults aged 7-50 years with that of three doses of DTaP-IPV-Hib Pentavalent Vaccine in Infants Aged 3 Months
- Trial name
- NCT07354269
- Testing
- sIPV, DTaP-IPV-Hib
- Where
- 3 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
COVID-19, Influenza
Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine
This study is an open-label, single-center, randomized phase IV clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04801888
- Testing
- Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28., Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Respiratory Syncytial Virus (RSV), RSV Infection
A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults
A phase 1, randomized, observer-blinded, parallel-controlled, dose escalation study in Australia will evaluate the safety and immunogenicity of the RSV vaccine candidate LYB005 with or without adjuvant in healthy adults aged 18…
- Trial name
- NCT06442241
- Testing
- LYB005 low dose without adjuvant, LYB005 middle dose without adjuvant, LYB005 high dose without adjuvant
- Where
- Australia
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy population aged 3 to…
- Trial name
- NCT05003479
- Testing
- SARS-CoV-2 Vaccine (Vero Cells), Inactivated
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangtai Biological Products Co., LTD
Influenza
Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)
The present study aims to evaluate safety, tolerability and immunogenicity of three lots of Chiron's cell-derived subunit influenza vaccine in healthy adult subjects as compared to a conventional egg-derived control vaccine…
- Trial name
- NCT00310804
- Testing
- Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV), Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV), Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)
- Where
- 2 sites in Lithuania
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Breast Neoplasms
Early Detection of Breast Cancer
The TriNetra™ Breast test is intended for use as a breast cancer screening test that evaluates Circulating Tumor Cells (CTCs) associated with breast cancer.
- Trial name
- NCT06043661
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Datar Cancer Genetics Inc
Herpes Zoster (HZ)
A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above.
- Trial name
- NCT06932523
- Testing
- Recombinant herpes zoster vaccine with low-dose adjuvant, Recombinant herpes zoster vaccine with high-dose adjuvant, Low-dose adjuvant
- Where
- China
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Respiratory Syncytial Virus (RSV)
Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine （CHO Cell） in Adults Aged 18 Years and Older
This phase 1 study in China will evaluate the Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older
- Trial name
- NCT07807449
- Testing
- Recombinant RSV Vaccine (CHO Cell), Adjuvant Suspension, Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Yikang Biotech (Suzhou) Co., Ltd.
Influenza, Human
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately 7700 male and female adults aged 50 years and older (approximately equally…
- Trial name
- NCT06015282
- Testing
- Investigational aQIVc, licensed QIVr, licensed aQIV
- Where
- 96 sites in United States, Canada and 6 more
- Volunteers
- 7,741 people, healthy volunteers welcome
- Sponsor
- Seqirus